All In Biotech

Drug Trial Radar · NCT07772960

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Oct 31, 2031

Study completion Oct 31, 2031

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 68 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

Conditions

  • Alcohol Use Disorder (AUD)
  • Obesity (BMI Equal to or >30)

Interventions

  • PlaceboOther

    Placebo - administered one weekly for 20 weeks

  • Semaglutide 1.0 mgDrug

    Semaglutide 1.0 mg low dose

  • Semaglutide 2.0 mgDrug

    Semaglutide 2.0 mg high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alcohol use daysTime frame: 20 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Stress Center

    New Haven, Connecticut · Recruiting

  • Yale Stress Center

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.